B7-33 (6mg)

What is B7-33?

Simplified relaxin-2 retaining anti-fibrotic and vasodilatory effects.

Listed vial contents: 6mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

B7-33 is a simplified single-chain analog of relaxin-2 that retains anti-fibrotic and vasodilatory properties. It activates RXFP1 to reduce collagen deposition, inhibit myofibroblast differentiation, and promote extracellular matrix remodeling.

What are the research questions?

• Organ fibrosis: Anti-fibrotic effects studied in cardiac, pulmonary, renal, and hepatic fibrosis models.
• Heart failure: Vasodilation and anti-fibrotic effects relevant to heart failure with preserved ejection fraction.
• Vascular function: Relaxin-mediated vasodilation improves blood flow and reduces vascular stiffness.

What does the published work describe?

Hossain MA et al. — B7-33 retains RXFP1 activation with anti-fibrotic and vasodilatory effects of native relaxin-2. Preclinical models show reduced cardiac and renal fibrosis.

What are the limits of this evidence?

The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.

Study references

1. Hossain MA et al. Chem Sci 2016

These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.